Argentina vs Georgia: Average cost of drugs for extensively drug-resistant tuberculosis
Argentina
4,721 constant 2022 US$
in 2024
Georgia
4,500 constant 2022 US$
in 2022
Argentina rank
12th
Georgia rank
14th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Argentina
- Georgia
How they compare
Argentina currently reports 4,721 constant 2022 US$ against 4,500 constant 2022 US$ in Georgia, a difference of 221 constant 2022 US$.
The two have swapped places 1 time across 5 shared years of data; in 2018 it was Argentina ahead.
Argentina ranks 12th and Georgia ranks 14th of 56 countries.
Georgia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Argentina | Georgia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 3,713 constant 2022 US$ | 5,250 constant 2022 US$ | 1,537 constant 2022 US$ | Georgia |
| 2020s | 1,904 constant 2022 US$ | 4,533 constant 2022 US$ | 2,630 constant 2022 US$ | Georgia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Argentina or Georgia?
- Argentina, at 4,721 constant 2022 US$ against 4,500 constant 2022 US$ in Georgia as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Argentina and Georgia?
- 221 constant 2022 US$, with Argentina ahead.
- How many years of comparable data are there for Argentina and Georgia?
- 5 years are reported by both, from 2018 to 2022.
- How do Argentina and Georgia rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Argentina ranks 12th and Georgia ranks 14th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.